John Peniston, DO
Family Medicine · Feasterville, PANPI 1265438642
Payments from drug & device makers
Across 268 payments — averaging $195.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$42K
- Kowa Research Institute, Inc.$6K
- Pfizer$590
- AstraZeneca$388
- Amgen$344
- Novo Nordisk$326
- plus $2K from 25 others
Across 11 payments — averaging $102.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Food & beverage$4,188100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $42,282 |
| Kowa Research Institute, Inc. | 3 | $6,350 |
| Pfizer | 40 | $590 |
| AstraZeneca | 28 | $388 |
| Amgen | 21 | $344 |
| Novo Nordisk | 21 | $326 |
| GSK | 17 | $306 |
| Lilly USA, LLC | 13 | $213 |
| Johnson & Johnson(2 entities) | 5 | $195 |
| Boehringer Ingelheim | 11 | $187 |
| Merck | 8 | $129 |
| Amarin Pharma, Inc. | 7 | $95 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $88 |
| Kowa Pharmaceuticals America, Inc. | 6 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $79 |
| Exact Sciences | 3 | $72 |
| Sumitomo Pharma America, Inc. | 3 | $68 |
| Sanofi Pasteur Inc. | 4 | $64 |
| Sanofi-aventis U.S. LLC | 3 | $64 |
| Bausch Health US, LLC | 3 | $56 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Inspire Medical Systems, Inc. | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Radius Health, Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Dexcom, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
- Tremfya$121
- SIMPONI ARIA$121
How this compares
$52,271 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 79 | $66,167 |
| JardianceEmpagliflozin | 52 | $26,500 |
| XareltoRivaroxaban | 31 | $22,912 |
| FarxigaDapagliflozin Propanediol | 18 | $16,636 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $11,401 |
| LivaloPitavastatin Calcium | 17 | $4,651 |
| Amlodipine-AtorvastatinAmlodipine/Atorvastatin | 14 | $3,969 |
| Metoprolol Succinate | 207 | $3,772 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $3,696 |
| Atorvastatin Calcium | 308 | $3,507 |
| Azelastine Hcl | 161 | $3,341 |
| Levemir FlexpenInsulin Detemir | 14 | $3,025 |
| Levothyroxine Sodium | 250 | $2,758 |
| Lisinopril | 269 | $2,645 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $590 | $66,16779 claims |
| Boehringer IngelheimJardiance | $187 | $26,50052 claims |
| Johnson & JohnsonXarelto | $195 | $22,91231 claims |
| AstraZenecaFarxiga | $388 | $16,63618 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $306 | $13,62829 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $82 | $4,65117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Feasterville
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.